Cerevance Ltd
- Active
- Large
- Holding
- 9 years
- 46 employees
- £6,759 (cur assets)
- £15,165 (revenue)
- 0-1m
- Regular importer
- Real address
- 3 directors
- 1 owner
- Cambridge
Two conditions of three:
1.Turnover > £36 million
2.Balance sheet total > £18 million
3.Average number of employees > 250
Field of Operation
Website
Social media
Summary
Cerevance Ltd from Cambridge UK: large company, holding company, active status, founded 8 years ago, 40 employees, £6,172 assets, yearly revenue: £17,660, real address, 3 directors, 1 owner. Regular importer of miscellaneous chemical products (31 months imported). It's a large company as it met two conditions of three: turnover more than £36 million, balance sheet more than £18 million, employees more than 250. The last reported current assets is £6,172, and the revenue is £17,660. The company operates in the research and experimental development on biotechnology industries.
Cerevance Ltd is a biopharmaceutical company focused on developing innovative treatments for brain diseases. Its website highlights a dual approach: a core business centered on drug discovery and development, and a related venture involving high-end piano restoration. The company’s website, Cerevance, emphasizes its commitment to identifying novel therapeutic targets using a proprietary technology called NETSseq. It also showcases a pipeline of product candidates targeting neurodegenerative, psychiatric, and CNS-controlled metabolic disorders. The company’s activities include clinical trials, preclinical research, and collaborations with other companies, like Merck.
Financially, Cerevance Ltd’s numbers present a mixed picture. While the company’s revenue is £17,660, its assets are surprisingly low at only £6,172. Bank borrowings increased by 2600%, reaching £2100, and cash reserves fell 29%, dropping to £2200. Creditors decreased by 23%, suggesting improved debt management. However, the company's large size (meeting two of three criteria for turnover over £36 million, balance sheet over £18 million, and more than 250 employees) suggests a more substantial operation than the asset figures imply. The lack of an auditor mentioned suggests that the company is exempt from an audit.
The company’s focus on research and development, coupled with its collaborations, indicates a long-term investment strategy. The small asset base and increased borrowings, however, suggest that it’s burning through cash, a common challenge for biopharmaceutical startups. The company’s focus on brain diseases, a complex and challenging area of research, adds another layer of risk—but also the potential for significant reward.
Registered in England/Wales under the registration number 10304008, with a registered address at CB4 0PZ, United Kingdom, Cambridge, 418 Cambridge Science Park Milton Road.
WARNING: The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.
Ports, countries, transport, and price/kg were calculated by CorpSignals; non-official data, may contain errors.
Owners & PSC
-
Corporate
- 5 years
- psc
-
Resident of United States
Managers
-
Individual
- 3 years
-
Resident of United Kingdom
-
Individual
- 6 years
-
Resident of United States
-
Individual
- 9 years
-
Resident of United Kingdom
Last reports
The latest confirmation statement submitted six months ago.
Last news
-
Confirmation statement made on 2025-07-28 with no updatesDownload 3 pages pdf report
-
Full accounts made up to 2024-12-31Download 24 pages pdf report
-
Full accounts made up to 2023-12-31Download 24 pages pdf report
Importer profile by HS codes
Click on the map to see detailed UK statistics on HS code, including companies list.
Import HS codes in detail
Last imported products
Click on items to see detailed UK statistics on HS code, including companies list.
* Warning: Ports, countries, transport, and price/kg were calculated by CorpSignals; non-official data, may contain errors.
FAQ about Cerevance Ltd
Looking for leads in the UK?
Book a demo—see how CorpSignals can help you find UK leads.